{"id":"W4212780237","doi":"10.1200/jco.2022.40.6_suppl.012","title":"Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Abiraterone acetate; Enzalutamide; Oncology; Progression-free survival; Cancer; Androgen deprivation therapy; Androgen receptor; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002094066,0.001665619,0.002004426,0.0005661951,0.0004705294,0.001412895,0.001169534,0.001540005,0.007708307],"category_scores_gemma":[0.001363849,0.0007722096,0.002298474,0.0004756561,0.0009423816,0.001141091,0.0006557367,0.003202625,0.001339735],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001153507,"about_ca_system_score_gemma":0.002349252,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001115058,"about_ca_topic_score_gemma":0.002866191,"domain_scores_codex":[0.9994444,0.0003293462,0.00002253448,0.00006474336,0.0000498318,0.00008913843],"domain_scores_gemma":[0.9990735,0.0001527085,0.0002442515,0.00008849669,0.00006917898,0.0003718109],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8961595,0.05162469,0.001762833,0.0007119883,0.0008484945,0.00009505728,0.0001471974,0.001053316,0.01483001,0.0002433847,0.0034633,0.02906029],"study_design_scores_gemma":[0.6993198,0.2919772,0.003923337,0.00005589123,0.0004203019,0.0001155988,0.00003417928,0.0004549091,0.001231403,0.0002230661,0.002221099,0.00002311576],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9725719,0.003146091,0.001237626,0.001074121,0.0003160209,0.01195472,0.004578426,0.0003790089,0.004742102],"genre_scores_gemma":[0.9582855,0.003208884,0.005150827,0.002497194,0.0005728241,0.01574829,0.006745805,0.0001231909,0.007667552],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007708307,"threshold_uncertainty_score":0.02578688,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08166941178403357,"score_gpt":0.4274364120016267,"score_spread":0.3457670002175932,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}